Cargando…

Changes in Quality of Life After Long-Term Biochemical Control of Acromegaly

Acromegaly results in impaired quality of life (QoL), which improves but does not normalize after biochemical control of growth hormone (GH) excess. There are few data regarding long-term QoL in patients with sustained biochemical control of acromegaly. We hypothesized that QoL would continue to imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimball, Allison, Dichtel, Laura E, Haines, Melanie S, Nachtigall, Lisa B, Swearingen, Brooke, Jones, Pamela, Tritos, Nicholas A, Mahoney, Claire, Gerweck, Anu, Miller, Karen K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090160/ http://dx.doi.org/10.1210/jendso/bvab048.1303

Ejemplares similares

MON-286 Peak Stimulated Growth Hormone Is Lower in Subjects with Nonalcoholic Fatty Liver Disease Than Controls of Similar Sex, Age and BMI
por: Dichtel, Laura E, et al.
Publicado: (2020)

SUN-455 Abnormalities in Bone Microarchitecture of Women with Active Acromegaly Using HR-pQCT
por: Paes Batista da Silva, Paula, et al.
Publicado: (2019)

OR27-2 Growth Hormone Reduces Hepatic Steatosis, Inflammation and Fibrosis in Adults with Overweight/Obesity and Nonalcoholic Fatty Liver Disease
por: Bartsch, Lea, et al.
Publicado: (2022)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

OR32-05 Lower Oxytocin Levels Are Associated with Lower Bone Mineral Density and Less Favorable Hip Geometry in Hypopituitary Men
por: Maso, Ana Aulinas, et al.
Publicado: (2020)

SAT-436 Adjuvant Therapeutic Modalities in Acromegaly: Clinical Course and Factors Predicting Biochemical Controls
por: Jung, Hyein, et al.
Publicado: (2019)

PMON132 Biochemical and Radiologic Discordance in the Post-operative Surveillance of a Filipino Patient With Acromegaly
por: Enverga, Mariel C, et al.
Publicado: (2022)

Assessment of the Severity of Carpal Tunnel Syndrome in Patients With Acromegaly: A Focus on Clinical, Biochemical and Image Outcomes
por: Paredes Vinueza, Diego Fernando, et al.
Publicado: (2021)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

ODP320 Immune Organs Enlarged in Acromegaly: Evaluation of Thymus Volume in Patients with Acromegaly
por: Nahit Sendur, Suleyman, et al.
Publicado: (2022)

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2021)

MON-449 Serum Neuroactive Steroid Levels in Postmenopausal Women with Treatment-Resistant Major Depressive Disorder
por: Dichtel, Laura, et al.
Publicado: (2019)

SUN-303 Effects of Open-Label, Adjunctive Ganaxalone Treatment on Resistant Depression in Postmenopausal Women: A Pilot Study
por: Dichtel, Laura E, et al.
Publicado: (2020)

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

MON-302 The Prevalence of Acromegaly in the Sleep Apnoea Clinic
por: Lynch, Julie Marie, et al.
Publicado: (2020)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

SAT-451 Acromegaly and Thyroid Cancer
por: Danilowicz, Karina, et al.
Publicado: (2019)

SAT-257 Coexisting Craniopharyngioma and Acromegaly
por: Yang, Almira, et al.
Publicado: (2020)

Pleurihormonal Pituitary Adenomas Presenting as Acromegaly
por: Schwehr, Megan, et al.
Publicado: (2021)

The Secret Behind Anemia in Patients With Acromegaly
por: Firlatan, Busra, et al.
Publicado: (2021)

THU025 Acromegaly And Central Hyperthyroidism
por: Akhtar, Ahmad, et al.
Publicado: (2023)

THU060 Time To First Remission, Medical Therapy And Survival In Acromegaly: UK Acromegaly Register (UKAR) Study
por: Deshmukh, Harshal, et al.
Publicado: (2023)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

Use of Oral Concomitant Medications in Patients With Acromegaly
por: Petersenn, Stephan, et al.
Publicado: (2021)

ODP314 Gynecomastia as the Initial Presentation of Acromegaly.
por: Lim, Frederick, et al.
Publicado: (2022)

ODP306 Diplopia as Presenting Manifestation of Acromegaly
por: Rjoob, Hani, et al.
Publicado: (2022)

FRI356 SIADH In Acromegaly And Cerebrovascular Accident
por: Simrampreet, Gill, et al.
Publicado: (2023)

Somatotroph Adenomas have a Predilection to Invade the Cavernous Sinus and Resection of the Medial Wall of the Cavernous Sinus Offers the Highest Potential for Biochemical Remission in Acromegaly
por: Mohyeldin, Ahmed, et al.
Publicado: (2021)

PMON61 Evaluation of elevated IGF-1 in patients without clinical evidence of acromegaly
por: Careless, Laura, et al.
Publicado: (2022)

SAT-267 Pregnancy in Acromegaly: Report of Five Cases
por: Burcea, Iulia Florentina, et al.
Publicado: (2020)

Pachydermoperiostosis: A Rare Masquerader of Acromegaly and Thyroid Acropachy
por: Alkaissi, Hussam R, et al.
Publicado: (2021)

THU022 A Case Of Delayed Diagnosis Of Acromegaly
por: Blanchard, Kayla, et al.
Publicado: (2023)

ODP348 Regional disparities in functional impairment due to arthropathy in patients with acromegaly.
por: Ahmad, Syed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k569evp9pc2qbj6rvc1cbfos09